News

According to a study of diabetic patients who underwent revascularization for multivessel coronary artery disease (CAD), patients treated with insulin experienced more major adverse cardiovascular events after revascularization than those not treated with insulin.

Home November 04, 2013
Home
News

A new study demonstrated that some patients may not need to receive prolonged anti-clotting therapy after drug-eluting stent (DES) implantation with the Endeavor zotarolimus-eluting stent, and that shortening the duration could reduce bleeding risks and treatment costs.

Home November 04, 2013
Home
Heart Attack_infarction_from St Jude Medical PR video_1
Feature

According to a new study, aspirating blood clots does not significantly reduce microvascular obstruction or reduce the risk of death in patients with non-ST-elevation myocardial infarction (NSTEMI), when compared to standard percutaneous coronary intervention (PCI) without thrombectomy. Findings from the TATORT-NSTEMI clinical trial were presented at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

Home November 04, 2013
Home
cath lab clinical trial study pharmaceuticals antiplatelet therapy arctic
Feature

Patients who do not experience a major cardiac event in the first year after receiving drug-eluting stent (DES) may not need to receive prolonged dual antiplatelet therapy (DAPT) according to the results from the ARCTIC-INTERRUPTION trial, which was presented at the 25th annual Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2013).

Home November 04, 2013
Home
heart valve repair hybrid or cath lab reprise II boston scientific lotus tct
Feature

In a clinical trial of the Boston Scientific Lotus valve, a second-generation transcatheter aortic valve, the device demonstrated low rates of complications that are sometimes seen in transcatheter aortic valve replacement (TAVR), including challenges with positioning, post-procedure paravalvular aortic regurgitation, vascular complications and stroke.

Home November 04, 2013
Home
Feature

A hybrid approach to treating coronary artery disease that involves a hybrid procedure combining a minimally invasive bypass surgery with percutaneous coronary intervention (PCI) was found to be feasible and safe in a clinical trial. This is the first randomized study of the technique.

Home November 04, 2013
Home
News

Direct Flow Medical Inc. announced six-month data from the fully enrolled DISCOVER CE mark trial of the Direct Flow Medical Transcatheter Aortic Valve System.

Home November 04, 2013
Home
Calgary Scientific_ResolutionMD Android_Devices
Feature | Dave Fornell

As the use of mobile computing devices and smartphones has rapidly proliferated in healthcare over the past few years, there has been a flood of medical applications (apps) developed for all facets of medicine. In an increasingly tech savvy world, people want information to be at their fingertips when and where they need it via their mobile devices.

Home November 04, 2013
Home
cath lab cardiac diagnostics genetic testing antiplatelet therapy blood monitors
Feature

According to a new study, genetic profiling of patients undergoing percutaneous coronary intervention (PCI) may help cardiology teams adjust treatment and improve ischemic outcomes for patients who do not properly metabolize thienopyridine blood thinning therapies such as clopidogrel.

Home November 04, 2013
Home
News

Abbott announced clinically meaningful changes to quality of life, a reduction in rehospitalization for heart failure and functional improvements for patients treated with the company's first-in-class, catheter-based MitraClip therapy for patients with degenerative mitral regurgitation (MR) who are at prohibitive risk for mitral valve surgery.

Home November 04, 2013
Home
tryton stent, bifurcation stenting
Feature

A clinical trial designed to measure the effectiveness of using a dedicated side branch-covering bare metal stent in true bifurcation coronary lesions found that that the strategy was safe, but the results did not establish non-inferiority compared to the currently accepted strategy of using a single stent with provisional use of a second side branch stent when indicated.

Home November 01, 2013
Home
News

In the first head-to-head randomized controlled trial of third-generation durable-polymer drug-eluting stents for the treatment of coronary artery disease in an all-comers patient population, the Medtronic Resolute Integrity and the Boston Scientific Promus Element performed similarly on all measures except longitudinal strength, which favored the Medtronic device.

Home November 01, 2013
Home
News

A new study showed that a conservative approach to revascularization for patients with intermediate coronary lesions determined by angiographic diameter stenosis is safe and non-inferior to an aggressive approach. Findings of the SMART-CASE trial were presented at the 25th annual Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2013).

Home November 01, 2013
Home
cath lab drug-eluting balloons stents bare metal clinical trial study RIBS V
Feature

A clinical trial comparing the use of drug-eluting stents (DES) and drug-eluting balloons (DEB) in treating in-stent restenosis (ISR) from bare metal stents found that both techniques yielded positive long term outcomes. Findings from the RIBS V trial were presented at the 25th annual Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2013).

Home November 01, 2013
Home
bifurcation stenting
Feature

A new clinical trial showed that a two-stent technique for treatment of bifurcation lesions with a large stenotic side branch was not associated with significant improved outcomes compared to a provisional stenting approach. The findings from the Nordic-Baltic Bifurcation IV study were presented at the 25th annual Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2013).

Home November 01, 2013
Home
Subscribe Now